GRAIL, Inc.: GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...
Future Market Insights2h
Cardiac Biomarker Diagnostic Test Kits Market Set to Reach USD 3,206.73 Million by 2033 at a 5.1%, Fueled by Rising Cardiovascular Disease Incidences
The global cardiac biomarker diagnostic test kits market is poised for significant growth, with an estimated market size of ...
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Lung12, patients will be screened with the GRAIL assay prior to surgery to inform eligibility for post-surgery randomization to an adjuvant treatment regimen ( NCT06564844 ). Assay performance was ...
Roche receives CE Mark for Ventana FOLR1 RxDx Assay
Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2024 Earnings Call Transcript
Good afternoon, ladies and gentlemen. Welcome to Plus Therapeutics Third Quarter 2024 Results Conference Call. Before we begin, we want to advise you that over the course of the call, including any ...
AZoLifeSciences on MSN22h
New Study Compares MALDI-TOF MS Assays for Detecting Carbapenemase Activity
Austrian researchers evaluate MALDI-TOF MS assays for carbapenemase detection, assessing their reliability and practicality ...